A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes

AIMS: To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D). METHODS: In a 24‐week double‐blind trial, 414 patients with T2D were randomized to omarigliptin 25 mg once weekly, sitagliptin 50 mg once daily or placebo. The double‐blind period was followed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655696/
https://www.ncbi.nlm.nih.gov/pubmed/28449368
http://dx.doi.org/10.1111/dom.12988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655696/
https://www.ncbi.nlm.nih.gov/pubmed/28449368
http://dx.doi.org/10.1111/dom.12988

Ejemplares similares